ClinicalTrials.gg
CompletedNCT02600494Updated Nov 3, 2025Results posted

Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression

A Phase 3 interventional study of ITI-007 (Lumateperone) and Placebo in Bipolar Depression, sponsored by Intra-Cellular Therapies, Inc.. Completed at 55 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-03.

Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
554
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies in Bipolar Disorder by Johnson & Johnson — 2 open to participants now, 2 under way, 2 of them phase 3. Bipolar Disorder · Johnson & Johnson.

Enrollment
4th of 36
554 · median 300
Started
2015
the only one that year
Phase 3
28 of 39
2 open now
Registered
30th of 39
by date

Among the 39 studies in Bipolar Disorder by Johnson & Johnson, this one is the 4th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2015, is one of 28 in phase 3, and was the 30th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 267 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

2 of the 39 studies in Bipolar Disorder by Johnson & Johnson are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 205 Bipolar Disorder studies recruiting now, 59 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 37 take children under 18; 50 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Bipolar Disorder by Johnson & Johnson, or all of them as a file.
02

Study summary

The study will evaluate the efficacy and safety of ITI-007 (Lumateperone) in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode. The study will be conducted in two parts, Part A and Part B. Part A is a randomized, double-blind, placebo-controlled study. In Part B, patients who safely complete participation in part A may be enrolled in an open-label extension.

03

Conditions studied

  • Bipolar Depression

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major Inclusion Criteria:

  • male or female subjects of any race, ages 18-75 inclusive, with a clinical diagnosis of Bipolar I or Bipolar II disorder
  • experiencing a current major depressive episode

Major Exclusion Criteria:

  • any subject unable to provide
  • any female subject who is pregnant or breast-feeding
  • any subject judged to be medically inappropriate for study participation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
554 participants (actual)

Study arms

  • Experimental
    40 mg ITI-007 (Lumateperone)

    40 mg ITI-007 (Lumateperone) administered orally as capsules once daily for 6 weeks

    Drug: ITI-007 (Lumateperone)

  • Experimental
    60 mg ITI-007 (Lumateperone)

    60 mg ITI-007 (Lumateperone) administered orally as capsules once daily for 6 weeks

    Drug: ITI-007 (Lumateperone)

  • Placebo comparator
    Placebo

    Placebo administered orally as visually-matched capsules once daily for 6 weeks

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Day 43 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

    The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.

    Time frame: 6 weeks

Secondary outcomes

  1. Time to First Sustained Response in Reduction of MADRS Total Score

    Time frame: 6 weeks

Other outcomes

  1. Change From Baseline to Day 175 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

    The MADRS total score from baseline to Day 175 for patients that rolled over into the extension portion of the study (Part B)

    Time frame: Day 175

  2. Adverse Events

    Incidence of Treatment-Emergent Adverse Events from baseline to Day 175 for patients that rolled over into the extension portion of the study (Part B)

    Time frame: Day 175

07

Results

Posted Nov 3, 2025

Participant flow

Part A (6 Week Double-Blind Treatment)
Participant flow — Part A (6 Week Double-Blind Treatment)
MilestoneLumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)Placebo
Started183185186
Number of patients randomized and took at least 1 dose of study drug180184185
Completed126113138
Not completed577248
Withdrew: Adverse event13154
Withdrew: Lack of efficacy242
Withdrew: Protocol violation131014
Withdrew: Physician decision234
Withdrew: Withdrawal by subject151114
Withdrew: Lost to follow-up122810
Withdrew: Non-compliant with site request010
Part B (6 Month Open-Label Treatment)
Participant flow — Part B (6 Month Open-Label Treatment)
MilestoneLumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)Placebo
Started01270
Completed0740
Not completed0530
Withdrew: Adverse event0120
Withdrew: Lack of efficacy040
Withdrew: Protocol violation080
Withdrew: Physician decision010
Withdrew: Withdrawal by subject0170
Withdrew: Lost to follow-up0110

Outcome measures

PrimaryChange From Baseline to Day 43 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.

Time frame:
6 weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline to Day 43 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
score on a scaleLumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)Placebo
Change From Baseline to Day 43 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score-18.9 ± 1.11-20.7 ± 1.16-19.7 ± 1.11
Statistical analysis
  • Lumateperone 28 mg (ITI-007 40 mg Tosylate) vs Placebo · Mixed Effects Model for Repeated Measure · p = 0.514 (p-value is Hochberg-adjusted) · Least squares mean difference: 0.9 · 95% CI -1.83 to 3.53
  • Lumateperone 42 mg (ITI-007 60 mg Tosylate) · Mixed Effects Model for Repeated Measure · p = 0.895 (p-value is Hochberg adjusted) · Least squares mean difference: -1.0 · 95% CI -3.73 to 1.79
SecondaryTime to First Sustained Response in Reduction of MADRS Total Score
Time frame:
6 weeks
Reported as:
Median · days
Time to First Sustained Response in Reduction of MADRS Total Score
daysLumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)Placebo
Time to First Sustained Response in Reduction of MADRS Total Score43 (36 to NA)38 (36 to NA)37 (30 to NA)
Statistical analysis
  • Lumateperone 28 mg (ITI-007 40 mg Tosylate) vs Placebo · Regression, Cox · p = 0.993 · Hazard ratio (hr): 1.00 · 95% CI 0.712 to 1.400
  • Lumateperone 42 mg (ITI-007 60 mg Tosylate) vs Placebo · Regression, Cox · p = 0.665 · Hazard ratio (hr): 0.93 · 95% CI 0.657 to 1.307
Other pre-specifiedChange From Baseline to Day 175 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

The MADRS total score from baseline to Day 175 for patients that rolled over into the extension portion of the study (Part B)

Time frame:
Day 175
Reported as:
Mean · units on a scale
Change From Baseline to Day 175 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
units on a scaleLumateperone 42 mg (ITI-007 60 mg Tosylate)
Change From Baseline to Day 175 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score-8.9 ± 10.76
Other pre-specifiedAdverse Events

Incidence of Treatment-Emergent Adverse Events from baseline to Day 175 for patients that rolled over into the extension portion of the study (Part B)

Time frame:
Day 175
Reported as:
Count of participants · Participants
Adverse Events
ParticipantsLumateperone 42 mg (ITI-007 60 mg Tosylate)
Headache26
Dry Mouth15
Dizziness13
Nausea13
Somnolence11
Anxiety10
Irritability8

Adverse events

Collected over From signing ICF until end of study procedures (~10 weeks), including 6 weeks of double-blind treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A Lumateperone 28 mg (ITI-007 40 mg Tosylate)0/180 (0%)5/180 (2.8%)72/180 (40%)
Part A Lumateperone 42 mg (ITI-007 60 mg Tosylate)0/184 (0%)0/184 (0%)67/184 (36.4%)
Part A Placebo1/185 (0.5%)1/185 (0.5%)31/185 (16.8%)
Part B Lumateperone 42 mg (ITI-007 60 mg Tosylate)0/127 (0%)4/127 (3.1%)55/127 (43.3%)
Most frequent serious events
Most frequent serious events
EventPart A Lumateperone 28 mg (ITI-007 40 mg Tosylate)Part A Lumateperone 42 mg (ITI-007 60 mg Tosylate)Part A PlaceboPart B Lumateperone 42 mg (ITI-007 60 mg Tosylate)
DepressionPsychiatric disorders1/1800/1840/1851/127
Suicidal IdeationPsychiatric disorders1/1800/1840/1851/127
Mental status changesPsychiatric disorders0/1800/1840/1851/127
colitis ulcerativeGastrointestinal disorders0/1800/1840/1851/127
ManiaPsychiatric disorders1/1800/1840/1850/127
Panic AttackPsychiatric disorders1/1800/1840/1850/127
Anemia postoperativeInjury, poisoning and procedural complications1/1800/1840/1850/127
Procedural hemorrhageInjury, poisoning and procedural complications1/1800/1840/1850/127
AsthmaRespiratory, thoracic and mediastinal disorders1/1800/1840/1850/127
AgressionPsychiatric disorders0/1800/1841/1850/127
Most frequent other events
Most frequent other events
EventPart A Lumateperone 28 mg (ITI-007 40 mg Tosylate)Part A Lumateperone 42 mg (ITI-007 60 mg Tosylate)Part A PlaceboPart B Lumateperone 42 mg (ITI-007 60 mg Tosylate)
HeadacheNervous system disorders35/18020/18410/18526/127
SomnolenceNervous system disorders21/18024/1847/18511/127
Dry MouthGastrointestinal disorders13/18015/1843/18515/127
NauseaGastrointestinal disorders12/18016/1847/18513/127
DizzinessNervous system disorders10/18015/1844/18513/127
AnxietyPsychiatric disorders1/1802/1843/18510/127
IrritabilityPsychiatric disorders3/1803/1841/1858/127
FatigueGeneral disorders11/1804/1843/1854/127
DiarrhoeaGastrointestinal disorders9/18010/1845/1854/127
VomitingGastrointestinal disorders5/18010/1840/1856/127

Baseline characteristics

All patients in Part A Safety Analysis set which contains all patients who received at least one dose of study medication.

Age, Continuous
Age, Continuous(years)Lumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)PlaceboTotal
Mean40.5 ± 12.1242.7 ± 11.8542.3 ± 13.1341.9 ± 12.40
Sex: Female, Male
Sex: Female, Male(Participants)Lumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)PlaceboTotal
Female109111114334
Male717371215
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Lumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)PlaceboTotal
White10010698304
Black or African American757280227
Asian1236
American Indian or Alaska Native0213
Native Hawaiian or Other Pacific Islander0112
Multiple4116
Not Reported0011
Montgomery Asberg Depression Rating Scale (MADRS)
Montgomery Asberg Depression Rating Scale (MADRS)(units on a scale)Lumateperone 28 mg (ITI-007 40 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)PlaceboTotal
Mean35.8 ± 6.0835.9 ± 5.7934.7 ± 5.8435.4 ± 5.92
08

Study locations

55 sites
  • Clinical Site
    Little Rock, Arkansas, United States
  • Clinical Site
    Rogers, Arkansas, United States
  • Clinical Site
    Cerritos, California, United States
  • Clinical Site
    Culver City, California, United States
  • Clinical Site
    Garden Grove, California, United States
  • Clinical Site
    Lemon Grove, California, United States
  • Clinical Site
    National City, California, United States
  • Clinical Site
    Oakland, California, United States
  • Clinical Site
    Oceanside, California, United States
  • Clinical Site
    Orange, California, United States
  • Clinical Site
    Pico Rivera, California, United States
  • Clinical Site
    Riverside, California, United States
  • Clinical Site
    San Diego, California, United States
  • Clinical Site
    San Marcos, California, United States
  • Clinical Site
    Santa Rosa, California, United States
  • Clinical Site
    Colorado Springs, Colorado, United States
  • Clinical Site
    Bradenton, Florida, United States
  • Clinical Site
    Fort Myers, Florida, United States
  • Clinical Site
    Jacksonville, Florida, United States
  • Clinical Site
    Lauderhill, Florida, United States
  • Clinical Site
    Miami, Florida, United States
  • Clinical Site
    North Miami, Florida, United States
  • Clinical Site
    Orlando, Florida, United States
  • Clinical Site
    Atlanta, Georgia, United States
  • Clinical Site
    Chicago, Illinois, United States
  • Clinical Site
    Hoffman Estates, Illinois, United States
  • Clinical Site
    Lake Charles, Louisiana, United States
  • Clinical Site
    Baltimore, Maryland, United States
  • Clinical Site
    Boston, Massachusetts, United States
  • Clinical Site
    O'Fallon, Missouri, United States
  • Clinical Site
    St Louis, Missouri, United States
  • Clinical Site
    Las Vegas, Nevada, United States
  • Clinical Site
    Berlin, New Jersey, United States
  • Clinical Site
    Cherry Hill, New Jersey, United States
  • Clinical Site
    Marlton, New Jersey, United States
  • Clinical Site
    Toms River, New Jersey, United States
  • Clinical Site
    Brooklyn, New York, United States
  • Clinical Site
    Cedarhurst, New York, United States
  • Clinical Site
    New York, New York, United States
  • Clinical Site
    Rochester, New York, United States
  • Clinical Site
    Staten Island, New York, United States
  • Clinical Site
    Cincinnati, Ohio, United States
  • Clinical Site
    Cleveland, Ohio, United States
  • Clinical Site
    Dayton, Ohio, United States
  • Clinical Site
    Garfield Heights, Ohio, United States
  • Clinical Site
    Oklahoma City, Oklahoma, United States
  • Clinical Site
    Allentown, Pennsylvania, United States
  • Clinical Site
    Norristown, Pennsylvania, United States
  • Clinical Site
    Philadelphia, Pennsylvania, United States
  • Clinical Site
    Memphis, Tennessee, United States
  • Clinical Site
    Austin, Texas, United States
  • Clinical Site
    Dallas, Texas, United States
  • Clinical Site
    Houston, Texas, United States
  • Clinical Site
    Petersburg, Virginia, United States
  • Clinical Site
    Everett, Washington, United States
09

References and documents

Publications

  • Durgam S, Lakkis H, Kozauer SG, Chen C, McIntyre RS. Efficacy of Lumateperone in depression associated with bipolar II disorder: a pooled analysis of late-phase clinical trials. CNS Spectr. 2025 Sep 29;30(1):e80. doi: 10.1017/S1092852925100564. PubMed 41017591 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Jan 2019, 37 months.

Results were first posted in Nov 2025, 6 years 9 months after primary completion. A results delay was requested in Jan 2020.

Of 29 industry-sponsored phase 3 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 49. This study's 37 months is above that.

Counting every sponsor, half of 43 studies reached it within 37 months; a quarter within 21 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2015
First posted
Nov 9, 2015
StartActual
Dec 15, 2015
Primary completionActual
Jan 28, 2019
CompletionActual
Jul 24, 2019
Results delay requested
Jan 27, 2020
Results first posted
Nov 3, 2025
Last update
Nov 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02600494
Responsible party
Sponsor
First posted
Nov 9, 2015
Start date
Dec 15, 2015
Primary completion
Jan 28, 2019
Completion
Jul 24, 2019
Results posted
Nov 3, 2025
Last update
Nov 3, 2025

Study contacts

Susan Kozauer, MD
study director · Intra-Cellular Therapies, Inc. (ITI)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumateperone

Start the discussion